Jushi Holdings (JUSHF) Income from Non-Controlling Interests (2021)
Jushi Holdings (JUSHF) posted quarterly Income from Non-Controlling Interests of -$2.3 million for Q4 2021, down 3682.26% quarter-over-quarter from -$62000.0 in Q3 2021.
Jushi Holdings (JUSHF) Income from Non-Controlling Interests (2021) Analysis & Trends
Jushi Holdings (JUSHF) has reported Income from Non-Controlling Interests for 1 consecutive years, with -$2.3 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Income from Non-Controlling Interests changed N/A year-over-year to -$2.3 million; the TTM figure through Sep 2022 stood at -$2.3 million (changed N/A YoY), while the FY2021 annual figure was -$2.8 million, down 45.28% from the prior year.
- Income from Non-Controlling Interests slipped to -$2.3 million in Q4 2021 per JUSHF's latest filing, from -$62000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$62000.0 in Q3 2021 and bottomed at -$2.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -2.35 Mn |
| Sep 30, 2021 | -62,000.00 |
| Jun 30, 2021 | -190,000.00 |